CN111249298B - Anticancer pharmaceutical composition containing maduramicin and cisplatin - Google Patents
Anticancer pharmaceutical composition containing maduramicin and cisplatin Download PDFInfo
- Publication number
- CN111249298B CN111249298B CN202010267845.2A CN202010267845A CN111249298B CN 111249298 B CN111249298 B CN 111249298B CN 202010267845 A CN202010267845 A CN 202010267845A CN 111249298 B CN111249298 B CN 111249298B
- Authority
- CN
- China
- Prior art keywords
- cisplatin
- maduramicin
- cells
- pharmaceutical composition
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960004316 cisplatin Drugs 0.000 title claims abstract description 43
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 title claims abstract description 43
- 230000001093 anti-cancer Effects 0.000 title claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 13
- RWVUEZAROXKXRT-VQLSFVLHSA-N maduramicin Chemical compound O1[C@@H](C)[C@H](OC)[C@@H](OC)C[C@H]1O[C@@H]1[C@H]([C@@]2(C)O[C@H](CC2)[C@@]2(C)O[C@]3(O[C@@H]([C@H](C)[C@@H](O)C3)[C@@H](C)[C@H]3[C@@H]([C@@H](OC)[C@H](C)[C@@](O)(CC(O)=O)O3)OC)CC2)O[C@@H]([C@@H]2[C@H](C[C@@H](C)[C@@](C)(O)O2)C)C1 RWVUEZAROXKXRT-VQLSFVLHSA-N 0.000 title claims description 42
- 229950006915 maduramicin Drugs 0.000 title claims description 40
- 239000000203 mixture Substances 0.000 claims abstract description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 17
- 201000005202 lung cancer Diseases 0.000 claims description 17
- 208000020816 lung neoplasm Diseases 0.000 claims description 17
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229940041181 antineoplastic drug Drugs 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 15
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- WQGJEAMPBSZCIF-HKSLRPGUSA-N Maduramicin Chemical compound N.O1[C@@H](C)[C@H](OC)[C@@H](OC)C[C@H]1O[C@@H]1[C@H]([C@@]2(C)O[C@H](CC2)[C@@]2(C)O[C@]3(O[C@@H]([C@H](C)[C@@H](O)C3)[C@@H](C)[C@H]3[C@@H]([C@@H](OC)[C@H](C)[C@@](O)(CC(O)=O)O3)OC)CC2)O[C@@H]([C@@H]2[C@H](C[C@@H](C)[C@@](C)(O)O2)C)C1 WQGJEAMPBSZCIF-HKSLRPGUSA-N 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 description 27
- 206010028980 Neoplasm Diseases 0.000 description 23
- 230000005764 inhibitory process Effects 0.000 description 14
- 229940079593 drug Drugs 0.000 description 11
- 238000011580 nude mouse model Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 8
- 241000699660 Mus musculus Species 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 4
- 208000003495 Coccidiosis Diseases 0.000 description 3
- 206010023076 Isosporiasis Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 210000001364 upper extremity Anatomy 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 201000009546 lung large cell carcinoma Diseases 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种含有马杜霉素和顺铂的抗癌药物组合物，所述组合物的组分为马杜霉素和顺铂；马杜霉素和顺铂的比例为1:0.625‑1:5。本发明的优点在于提供了一种新型的抗癌药物组合物，马杜霉素与顺铂联用，此组合物提高了抗癌效果，毒副作用降低。
The invention discloses an anticancer pharmaceutical composition containing maduramycin and cisplatin. The components of the composition are maduramycin and cisplatin; the ratio of maduramycin and cisplatin is 1:0.625 ‑1:5. The invention has the advantage of providing a novel anticancer pharmaceutical composition, which is used in combination with maduramycin and cisplatin. The composition improves the anticancer effect and reduces the toxic and side effects.
Description
Technical Field
The invention relates to the field of medicines, and in particular relates to an anticancer pharmaceutical composition containing maduramicin and cisplatin.
Background
The incidence of cancer is increasing year by year and the trend toward younger cancers is due to the increased pollution of living environment and the increased pressure of life. Relevant statistics shows that the number of people who die due to cancer in China is up to 281 thousands of people, and the number of people who die due to cardiovascular and cerebrovascular diseases is already higher, so that the cancer poses a serious threat to the life safety of people in China. Meanwhile, lung cancer is the malignant tumor with the highest incidence in China, about 39.9 ten thousand cases of lung cancer are newly increased every year, and about 59.1 ten thousand cases of lung cancer death are caused every year. Lung cancer is classified into non-small cell lung cancer (NSCLC) and Small Cell Lung Cancer (SCLC), wherein the incidence rate of non-small cell lung cancer is the highest, accounting for more than 85% of all lung cancer incidence rates. The prevalence of lung cancer has increased over the past twenty years. Scientists expect that the number of patients will reach about 100 million people every year in 2025, and the number of patients with lung cancer in China will jump the world first at that time, so research on lung cancer treatment means becomes a problem to be solved urgently at present.
To date, there are three main treatments for lung cancer, surgical resection, radiotherapy and chemotherapy. Surgical treatment is the most effective method, but is limited to the early stage of lung cancer, and in recent years, the development of new nano-drug carriers and immunotherapy provide a new approach for treating lung cancer. Non-small cell lung cancer (NSCLC) has no obvious symptoms in the early stage of the disease and has certain concealment, so when the patient finds the disease, the cancer often reaches uncontrollable stage or even reaches the advanced stage of the cancer, and only the method of radiotherapy and chemotherapy can be used for treating the cancer. Radiotherapy and chemotherapy have many disadvantages, such as: the side effect of the medicine is great; has great negative effect on the physical health of the patient; the postoperative life of the patient faces the problems of low immunity, weak constitution and the like. Despite the recent further development of personalized lung cancer treatment regimens, the prognosis of lung cancer patients remains poor, with a 5-year survival rate of only 16% after surgery. With the progress of treatment, serious side effects are generated on normal cells. Therefore, a new anti-cancer drug with low toxicity and high efficiency needs to be found.
Maduramicin (Maduramicin) is a polyether ionophore antibiotic developed by cyanamide company in America, is widely applied to feed additives before, and has good killing activity on coccidiosis suffered by poultry. The anti-coccidiosis drug has the advantages of wide anti-coccidiosis spectrum, high efficiency, small drug resistance, relatively low price and the like, and is very wide in application. However, maduramicin has obvious toxicity to animals such as rabbits and horses, and the dosage of maduramicin needs to be paid attention to when the maduramicin is used. The maduramicin has a molecular weight of 934.163 and a molecular formula of C47H83NO17The chemical structure is shown in the figure1; structurally, maduramicin can be selectively combined with metal ions, so that the concentration of Na +/K + ions in cells is influenced, the charge balance on cell membranes is broken, and the apoptosis of the cells is further triggered.
The maduramicin can inhibit the proliferation of chicken myocardial cell lines and induce the cell lines to block in the G1 phase, so that the phenomena of myocardial cell apoptosis, autophagy and the like are promoted, which proves that the maduramicin can inhibit the proliferation capacity of myocardial cells.
Cisplatin, named Cisplatin in English, has the molecular formula Cl2H6N2Pt, molecular weight 300.05. Cisplatin cross-links to DNA strands and exhibits cytotoxic effects. After dissolution, the cell membrane can pass through the charged cell membrane without carrier transportation in vivo. Because the concentration of intracellular chloride ions is low (4mmol/L), the chloride ions are replaced by water, the charge is positive, the double-function group has the function similar to an alkylating agent, the double-function group can be combined with the basic group of DNA in a cell nucleus to form three forms of cross-linking, DNA damage is caused, DNA replication and transcription are damaged, and the synthesis of RNA and protein is inhibited at high concentration. Cisplatin has the advantages of wide anticancer spectrum, effectiveness of hypoxic cells, strong action and the like, is widely used for treating testicular cancer, ovarian cancer, uterine cancer, bladder cancer, neck cancer, prostatic cancer, brain cancer and the like, and has obvious curative effect. However, cisplatin has toxicity and side effects when used for treating cancer.
Therefore, the combined use of maduramicin and cisplatin can be tried to improve the treatment effect and reduce the toxic and side effects.
Disclosure of Invention
In order to solve the technical defects, the invention provides the application of maduramicin and cisplatin in preparing anti-cancer drugs.
The invention is realized by the following technical scheme:
the invention provides an anticancer pharmaceutical composition, which comprises maduramicin and cisplatin.
Preferably, the ratio of maduramicin to cisplatin is 1:0.625-1: 5.
More preferably, the ratio of maduramicin to cisplatin is 1:0.625 or 1:1.25, 1:2.5, 1: 5.
More preferably, the dose of maduramicin and cisplatin is 6mg/kg maduramicin +3mg/kg cisplatin.
The invention provides application of the anticancer medicine composition in preparing anticancer medicines.
The invention provides an application of an anticancer medicine composition in preparing an anti-lung cancer medicine.
The invention has the beneficial effects that: the invention has the advantages that a novel anticancer pharmaceutical composition is provided, and the maduramicin and the cisplatin are combined, so that the composition improves the anticancer effect and reduces the toxic and side effects.
Drawings
FIG. 1 shows the molecular structure of maduramicin.
Detailed Description
Example 1 synergistic inhibition of A549 cells and H460 cells by the combination of Madurycin and cisplatin
A549 cells (human lung adenocarcinoma cells), H460 cells (human large cell lung carcinoma cells) and Wi-38 cells (human embryonic lung cells) in logarithmic growth phase and good morphology were washed with PBS, digested with 0.25% pancreatin and blown into single cell suspensions. After conventional counting, the cell concentration was adjusted to 4X 104The cells/mL were inoculated in a 96-well plate at 100 μ L/well. At 37 ℃ with 5% CO2After culturing for 24h in a saturation humidity incubator, adding a drug to be detected, continuing culturing for a period of time, adding 20 mu L MTT, incubating for 4h, and detecting a light absorption value at 570nm in an enzyme labeling instrument.
Inhibition = 1- (experimental OD-blank OD)/(solvent control OD-blank OD) × 100%.
The interaction coefficient of the two medicines Q = E (A + B)/(EA + EB-EA x EB), E (A + B) means the inhibition rate of A, B on cells by the combination of the two medicines, and EA and EB mean the inhibition rate of A, B on cells respectively. When Q is more than 1.15, the two medicines have synergistic effect; when Q = 0.85-1.15, the two medicines have addition effect; when Q is less than 0.85, the two medicines show antagonism.
The results show that the inhibition effect of maduramicin and cisplatin on the proliferation of A549 cells and H460 cells is remarkably stronger than that of maduramicin or cisplatin alone on the proliferation of the two cells, and the maduramicin and cisplatin show obvious synergistic effect on the A549 cells and the H460 cells (Table 1 and Table 2). Whereas the inhibition of Wi-38 cell proliferation by maduramicin in combination with cisplatin was shown to be additive (Table 3).
TABLE 1 proliferation inhibition of A549 cells by Madurycin in combination with cisplatin
TABLE 2 proliferation inhibition of H460 cells by the combination of maduramicin and cisplatin
TABLE 3 inhibition of Wi-38 cell proliferation by maduramicin in combination with cisplatin
Example 2 inhibition of Madurycin and cisplatin combination in mouse transplanted Lung cancer A549
Establishing a nude mouse lung cancer transplantation tumor model: dilution of A549 cells with physiological saline to 1.2X 107and/mL, inoculating 0.2mL of the tumor-bearing male nude mice to the armpits of the upper limbs of male nude mice for experiments respectively, establishing a transplantation tumor model of the nude mice, and then randomly dividing the tumor-bearing male nude mice into a control group, a cisplatin group, a maduramicin group and a combined treatment group, wherein each group comprises 10 mice.
And (3) drug treatment: when the tumor grows to about 1.0cm, the medicine is administered by tail vein injection. The control group is injected with 0.2mL of physiological saline, the concentration of the antitumor drug taxol added to the armpit of the upper limb of the nude mouse in the cis-platinum group is 3mg/kg, the concentration of the maduramicin added to the armpit of the upper limb of the nude mouse in the maduramicin group is 6mg/kg, and the combined treatment group is 3mg/kg of cis-platinum and 6mg/kg of maduramicin. Tumor diameter (A) and tumor transverse diameter (B) were measured every three days with a vernier caliper, and tumor volume was calculated according to the formula V = π/6 × (A/2+ B/2)3, and tumor size was counted.
24h after the last administration, the nude mice were weighed and the tumor volume was counted.
The results show that the inhibition rates of the maduramicin or the cisplatin on the A549 cells are respectively 16.75% and 33.6%, the combined action of the maduramicin and the cisplatin enhances the tumor inhibition effect, the tumor inhibition rate reaches 69.8%, the growth of the tumor is obviously inhibited, the CDI value is 1.56, and the two drugs show obvious synergistic action (Table 4). The weight of the control group, the cisplatin-treated group and the maduramicin-treated group was significantly reduced, and the weight of the combination-treated group was not significantly changed (table 4).
TABLE 4 inhibition of the combination of maduramicin and cisplatin in mouse transplanted Lung carcinoma A549
Example 3 Effect of Madurycin in combination with cisplatin on the blood routine in tumor-bearing mice
The experimental animal modeling and grouping administration method are the same as above. 24h after the last administration, the nude mice are weighed, 0.5 mL of 0.5% heparin is injected into each abdominal cavity, the eyeballs are removed after heparinization, blood is taken, and the concentration of white blood cells, red blood cells and platelets in the blood routine is detected by whole blood.
The results show that the numbers of white blood cells, red blood cells and platelets in the control group and the combination treatment group are close to each other and are obviously higher than those in the cisplatin treatment group and the maduramicin treatment group (Table 5). The combination of maduramicin and cisplatin is shown to reduce toxic and side effects.
TABLE 5 Effect of Madurycin in combination with cisplatin on blood conventions in tumor-bearing mice
The foregoing is only a preferred embodiment of this patent, and it should be noted that, for those skilled in the art, various modifications and substitutions can be made without departing from the technical principle of this patent, and these modifications and substitutions should also be regarded as the protection scope of this patent.
Claims (6)
1. An anticancer pharmaceutical composition, which is characterized in that: the components of the composition are maduramicin and cisplatin.
2. The anticancer pharmaceutical composition according to claim 1, wherein: the ratio of the maduramicin to the cisplatin is 1:0.625-1: 5.
3. The pharmaceutical composition of claim 2, wherein: the ratio of the maduramicin to the cisplatin is 1:0.625 or 1:1.25, 1:2.5 and 1: 5.
4. The pharmaceutical composition of claim 2, wherein: the dose of the maduramicin and the cisplatin is 6mg/kg of maduramicin and 3mg/kg of cisplatin.
5. The use of an anticancer pharmaceutical composition according to any one of claims 1-4 in the preparation of an anticancer drug.
6. The use of the anticancer pharmaceutical composition according to any one of claims 1 to 4 for the preparation of an anti-lung cancer medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010267845.2A CN111249298B (en) | 2020-04-08 | 2020-04-08 | Anticancer pharmaceutical composition containing maduramicin and cisplatin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010267845.2A CN111249298B (en) | 2020-04-08 | 2020-04-08 | Anticancer pharmaceutical composition containing maduramicin and cisplatin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111249298A CN111249298A (en) | 2020-06-09 |
| CN111249298B true CN111249298B (en) | 2021-03-12 |
Family
ID=70943480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010267845.2A Active CN111249298B (en) | 2020-04-08 | 2020-04-08 | Anticancer pharmaceutical composition containing maduramicin and cisplatin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111249298B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009148581A1 (en) * | 2008-06-03 | 2009-12-10 | Qlt Usa, Inc. | Biocompatible oligomer-polymer compositions |
| CN103118670A (en) * | 2010-06-01 | 2013-05-22 | 欧鲁普雷图联邦大学 | Nanoparticulate composition containing antibiotics for intramammary administration in animals |
| CN109414419A (en) * | 2016-06-15 | 2019-03-01 | 德国癌症研究中心 | Treatment of cancer is carried out by targeted energy metabolism simultaneously and internal pH |
| CN109462995A (en) * | 2016-05-04 | 2019-03-12 | 波涛生命科学有限公司 | The method and composition of bioactivator |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1973824A (en) * | 2006-12-20 | 2007-06-06 | 山东蓝金生物工程有限公司 | Anticancer composition containing both platinum compound and Sirolimus |
| CN104548097A (en) * | 2013-10-14 | 2015-04-29 | 上海市肿瘤研究所 | Application of drug composition of tunicamycin and platinum anticancer drugs in treatment of liver cancer |
| EP3694489A4 (en) * | 2017-10-11 | 2021-06-30 | Illustris Pharmaceuticals, Inc. | METHOD AND COMPOSITION OF TOPICAL ADMINISTRATION |
| CN110606870B (en) * | 2019-09-18 | 2021-02-19 | 广东省农业科学院动物卫生研究所 | Polypeptide for preventing and treating eimeria tenella and pharmaceutical composition containing polypeptide |
-
2020
- 2020-04-08 CN CN202010267845.2A patent/CN111249298B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009148581A1 (en) * | 2008-06-03 | 2009-12-10 | Qlt Usa, Inc. | Biocompatible oligomer-polymer compositions |
| CN103118670A (en) * | 2010-06-01 | 2013-05-22 | 欧鲁普雷图联邦大学 | Nanoparticulate composition containing antibiotics for intramammary administration in animals |
| CN109462995A (en) * | 2016-05-04 | 2019-03-12 | 波涛生命科学有限公司 | The method and composition of bioactivator |
| CN109414419A (en) * | 2016-06-15 | 2019-03-01 | 德国癌症研究中心 | Treatment of cancer is carried out by targeted energy metabolism simultaneously and internal pH |
Non-Patent Citations (6)
| Title |
|---|
| [99mTc]Tc-duramycin, a potential molecular probe for early prediction of tumor response after chemotherapy;Li Y. et al;《Nuclear Medicine and Biology》;20181231;第66卷;第18-25页 * |
| Competitive electrochemical immunosensor for maduramicin detection by multiple signal amplification strategy via hemin@Fe-MIL-88NH2/AuPt;Hu M. et al;《Biosensors and Bioelectronics》;20190731;第142卷;第1-8页 * |
| Maduramicin induces apoptosis through ROS-PP5-JNK pathway in skeletal myoblast cells and muscle tissue;Chen X. et al;《Toxicology》;20190620;第424卷;第1-8页 * |
| Maduramicin Inhibits Proliferation and Induces Apoptosis in Myoblast Cells;Chen X. et al;《PLOS ONE》;20141222;第1-22页 * |
| 凝血酶体外促进肺癌细胞Glc-82周期进程和增殖及其分子机制;许芝山 等;《军事医学》;20120229;第36卷(第2期);第128-132页 * |
| 马杜霉素对人体健康危害及其检测方法研究进展;张小辉 等;《中国公共卫生》;20130131;第29卷(第1期);第145-147页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111249298A (en) | 2020-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114848589A (en) | Medicinal solution with anti-tumor synergistic attenuation effects and medicinal composition containing medicinal solution | |
| US20110021620A1 (en) | Use of tea polyphenols in preparing medicaments for prevention or treatment of tumors | |
| CN111249298B (en) | Anticancer pharmaceutical composition containing maduramicin and cisplatin | |
| CN107260734B (en) | Compound pharmaceutical composition with anti-lung cancer effect and application thereof | |
| CN105476996A (en) | Application of curcumin and afatinib for combined treatment of non-small cell lung cancer | |
| TWI874617B (en) | Astragalus pharmaceutical composition enhances the use of cancer treatment | |
| US10441564B2 (en) | Fructose analogs and their combinations as anti-cancer agents | |
| CN111249268B (en) | A binary composition containing maduramycin and paclitaxel | |
| CN105982888B (en) | A kind of combination medicine and application thereof containing qinghaosu and taxol | |
| CN104055786B (en) | The application in preparation preventing and treating tumour medicine of medicagenic acid-3-O-β-D-pyranglucoside, medicagenic acid and salt thereof | |
| CN111494385B (en) | A kind of medicine for the treatment of ovarian cancer and its preparation method and use | |
| CN115487185A (en) | Application of G007-LK in the treatment of small cell lung cancer | |
| CN113893338A (en) | Application of CD38 CAR-T cells in acute myelopathy of chronic myelocytic leukemia | |
| WO2023216281A1 (en) | Use of 3-hydroxyflavone in preparation of drug for treating mll gene rearrangement acute myeloid leukemia | |
| CN106668061B (en) | An anticancer drug composition containing cisplatin | |
| CN107412736B (en) | Anti-tumor combined medicine and application thereof in preparing anti-cancer medicine | |
| KR20140035974A (en) | Combined pharmaceutical compositions for the treatment of tumours | |
| CN111202743A (en) | Anticancer medicine composition combining maduramicin and vincristine | |
| CN102319260A (en) | The application of cisplatin combined itraconazole isomer in preparation treatment lung-cancer medicament | |
| CN112618569A (en) | Medicine for treating urothelial cancer | |
| CN110151824A (en) | A kind of pharmaceutical composition and preparation method thereof for treating hypopharyngeal cancer | |
| CN115227690B (en) | Application of alantolactone in double-expression type B cell lymphoma | |
| CN105497001A (en) | Use of resveratrol polymer in prevention and treatment of myelosuppression | |
| CN111840523B (en) | A kind of anticancer pharmaceutical composition containing active protein and active fatty acid | |
| CN110772513B (en) | a drug to treat leukemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |